People News: Affymetrix, Infinity Pharmaceuticals and Sirius Genomics

Share this article:
Affymetrix hired Dr. Andrew Last as chief commercial officer. Last has about 25 years of global experience in the life science, pharmaceutical, diagnostics and agrochemical industries, having held senior-management positions at Monsanto, Incyte Genomics, Applied Biosystems and Becton Dickinson.
Biotech firm Infinity Pharmaceuticals promoted Adelene Perkins to CEO, from president and chief business officer. Perkins will also join Infinity's board of directors. She has worked at Bain & Co., the Genetics Institute and TransForm Pharmaceuticals. Infinity's founder and current CEO, Steven Holtzman, will continue to work full time as executive chairman of the board.

Sirius Genomics, a developer of pharmacogenomic diagnostics, appointed Chris Wagner president and CEO, replacing Dr. Brad Popovich. Wagner has over 17 years of experience in marketing, sales and business development, having held positions with Aspreva Pharmaceuticals and Eli Lilly. Popovich will continue as a member of Sirius Genomics Board.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.